Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + lenvatinib with or without belzutifan in advanced solid tumors
NL-OMON60780Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, lenvatinib, belzutifan in hepatocellular carcinoma (HCC), colorectal cancer (CRC), pancreatic adenocarcinoma (PDAC), biliary cancer, endometrial cancer (EC), sponsored by Merck & Co.. Started Aug 2021; status: completed.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)colorectal cancer (CRC)pancreatic adenocarcinoma (PDAC)biliary cancerendometrial cancer (EC)
Beyond the preview
Go deeper on NL-OMON60780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60780.